Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Duffy Website

Austin G. Duffy, M.D.

Selected Publications

1)  Duffy A, Zhao F, Haile L, Gamrekelashvili J, Fioravanti S, Ma C, Kapanadze T, Compton K, Figg WD, Greten TF.
Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies.
Cancer Immunol. Immunother. 62: 299-307, 2013.
2)  Duffy AG, Greten TF.
Immunological off-target effects of standard treatments in gastrointestinal cancers.
Ann. Oncol. 25: 24-32, 2014.
3)  Greten TF, Duffy AG, Korangy F.
Hepatocellular carcinoma from an immunologic perspective.
Clin. Cancer Res. 19: 6678-85, 2013.
4)  Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP, O'Reilly EM.
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Ann. Oncol. 19: 86-91, 2008.
5)  Duffy A, Wilkerson J, Greten TF.
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.
Hepatology. 57: 1068-77, 2013.
6)  Abi-Jaoudeh N, Duffy AG, Greten TF, Kohn EC, Clark TW, Wood BJ.
Personalized oncology in interventional radiology.
J Vasc Interv Radiol. 24: 1083-92, 2013.
7)  Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C.
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
Clin. Cancer Res. 17: 5755-64, 2011.
Click Here to View Expanded Bibliography.

This page was last updated on 7/11/2014.